Intravitreal bevacizumab in the management of neovascular age-related macular degeneration: Effect of baseline visual acuity Academic Article uri icon

Overview

MeSH Major

  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal, Humanized
  • Visual Acuity
  • Wet Macular Degeneration

abstract

  • Intravitreal bevacizumab for eyes with neovascular age-related macular degeneration and baseline visual acuity better than 70 letters was safe and able to maintain this vision over 12 months.

publication date

  • October 2013

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1097/IAE.0b013e3182877a0d

PubMed ID

  • 23615342

Additional Document Info

start page

  • 1828

end page

  • 35

volume

  • 33

number

  • 9